Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06/23 Global Zolpidem Tartrate Market 2017 - FARMAK, Bachem, Sanofi, Aarti Group, G..
06/22 NEW TYPE 2 DIABETES FINDINGS FROM SA : Post-GWAs strategies for...
06/21 EU COURT : Vaccines can be blamed for illnesses without proof
06/21 SANOFI : EFPIA Appoints New President and Vice Presidents
06/19 SANOFI : Disclosure of trading in own shares
06/19 ARTEMISININ DERIVATIVES MARKET : Sanofi, KPC Pharmaceuticals, Guangxi Xiancaotan..
06/17 SANOFI : outlines 600m biologics manufacturing investment plan
06/16 SANOFI : Launches 'Action 2017', Worldwide Employee Stock Purchase Plan
06/16 SANOFI : Launches "Action 2017", a Worldwide Employee Stock Purchase Plan
06/16 Global Zika Virus Market 2017- Bharat Biotech, Inovio Pharmaceuticals and Gen..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/21 AMICUS THERAPEUTICS : Elucidating The Bullish And Bearish Claims
06/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 19, 2017
06/18 SANOFI : A Good Bet On Pharma
06/15 PAREXEL teams up with Sanofi to advance the use of wearable devices to collec..
06/14 Sanofi all in with biologics production - Reuters
Advertisement
Financials (€)
Sales 2017 36 766 M
EBIT 2017 9 472 M
Net income 2017 7 964 M
Debt 2017 4 336 M
Yield 2017 3,46%
P/E ratio 2017 14,09
P/E ratio 2018 18,28
EV / Sales 2017 3,16x
EV / Sales 2018 3,03x
Capitalization 111 740 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -3,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI15.28%124 760
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
MERCK AND COMPANY12.15%180 576
More Results